BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 16105753)

  • 1. Runx1/AML1 in normal and abnormal hematopoiesis.
    Yamagata T; Maki K; Mitani K
    Int J Hematol; 2005 Jul; 82(1):1-8. PubMed ID: 16105753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.
    Lam K; Zhang DE
    Front Biosci (Landmark Ed); 2012 Jan; 17(3):1120-39. PubMed ID: 22201794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core binding factor genes and human leukemia.
    Hart SM; Foroni L
    Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
    Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Runx1/AML1 in leukemia: disrupted association with diverse protein partners.
    Perry C; Eldor A; Soreq H
    Leuk Res; 2002 Mar; 26(3):221-8. PubMed ID: 11792409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Runx1/AML-1 ranks as a master regulator of adult hematopoiesis.
    Ichikawa M; Asai T; Chiba S; Kurokawa M; Ogawa S
    Cell Cycle; 2004 Jun; 3(6):722-4. PubMed ID: 15213471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
    Osato M
    Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
    Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
    Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications.
    Asou N
    Crit Rev Oncol Hematol; 2003 Feb; 45(2):129-50. PubMed ID: 12604126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis.
    Kalev-Zylinska ML; Horsfield JA; Flores MV; Postlethwait JH; Vitas MR; Baas AM; Crosier PS; Crosier KE
    Development; 2002 Apr; 129(8):2015-30. PubMed ID: 11934867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.
    Ganly P; Walker LC; Morris CM
    Leuk Lymphoma; 2004 Jan; 45(1):1-10. PubMed ID: 15061191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells.
    Okumura AJ; Peterson LF; Lo MC; Zhang DE
    Exp Hematol; 2007 Jun; 35(6):978-88. PubMed ID: 17533052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.
    Yuan Y; Zhou L; Miyamoto T; Iwasaki H; Harakawa N; Hetherington CJ; Burel SA; Lagasse E; Weissman IL; Akashi K; Zhang DE
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10398-403. PubMed ID: 11526243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 8;21 translocation in leukemogenesis.
    Peterson LF; Zhang DE
    Oncogene; 2004 May; 23(24):4255-62. PubMed ID: 15156181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
    Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
    Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
    Peterson LF; Lo MC; Okumura AJ; Zhang DE
    Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice.
    Tsuzuki S; Seto M; Greaves M; Enver T
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8443-8. PubMed ID: 15155899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
    Hyde RK; Zhao L; Alemu L; Liu PP
    Leukemia; 2015 Aug; 29(8):1771-8. PubMed ID: 25742748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
    Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
    Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.